Concerning the final report “Hyperthermia: a systematic review” of the Ludwig Boltzmann Institute for Health Technology Assessment, Vienna, March 2010

Sauer, Rolf; Creeze, H.; Hulshof, M.C.C.M.; Issels, Rolf D.; Ott, Oliver J.

doi:10.1007/s00066-012-0072-9

Cited by 13 publications

(10 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Hyperthermia has been used as cancer therapy for decades, especially for its benefits in enhancing chemotherapy and radiotherapy efficacy[ 6 , 14 - 22 ]. mEHT has been more recently introduced among hyperthermia methods, targeting malignant cell membranes and the extracellular matrix and overcoming the issue of homogenous tissue heating[ 7 , 8 ].…”

Section: Discussionmentioning

confidence: 99%

Modulated electro-hyperthermia in stage III and IV pancreatic cancer: Results of an observational study on 158 patients

Fiorentini¹,

Sarti²,

Ranieri³

et al. 2021

WJCO

View full text Add to dashboard Cite

BACKGROUND An increasing number of studies report the beneficial effects of regional hyperthermia in association with chemotherapy (CHT) and radiotherapy for the treatment of pancreatic cancer; in particular, the use of modulated electro-hyperthermia (mEHT) results in increased survival and tumor response. AIM To compare outcomes of CHT alone or in association with mEHT for the treatment of stage III and IV pancreatic cancer. METHODS This was an observational retrospective study; data were collected for patients with stage III-IV pancreatic cancer that were treated with CHT alone or in combination with mEHT from 2003 to 2019. A total of 158 patients were included in the study out 270 patients screened in four Italian hospitals; 58 (37%) of these received CHT + mEHT and 100 (63%) CHT. CHT was mainly gemcitabine-based regimens in both groups. RESULTS Overall (19.5 mo vs 11.02 mo, P < 0.001) and progression-free (12 mo vs 3 mo, P < 0.001) survival were better for the CHT + mEHT group compared to the CHT group. The association of mEHT resulted also in an improvement of tumor response with disease control rate 95% vs 58% ( P < 0.001) at 3 mo. Toxicity was comparable in the two study groups, and mEHT related adverse events were limited in 8 patients presenting G1-2 skin burns. CONCLUSION The addition of mEHT to systemic CHT improved overall and progression-free survival and local tumor control with comparable toxicity.

show abstract

Section: Discussionmentioning

confidence: 99%

Modulated electro-hyperthermia in stage III and IV pancreatic cancer: Results of an observational study on 158 patients

Fiorentini¹,

Sarti²,

Ranieri³

et al. 2021

WJCO

View full text Add to dashboard Cite

show abstract

“…The role of hyperthermia in the treatment of cancer has been summarized in the article published by The German Cancer Society in 2012 in Sthrahlenther Oncol by Sauer, R et al and this publication is an explanatory text about the subject. HT is recommended especially in primary tumors and local recurrences (23). HT is more than likely the most powerful radio-and chemo-sensitizer to date.…”

Section: Discussionmentioning

confidence: 99%

Evaluation of Oncological Hyperthermia Centers and Turkey Modeling Oncological Hyperthermia Centers and Turkey Modeling

Göksel

Demircioglu

2020

Preprint

View full text Add to dashboard Cite

Background Hyperthermia is a radio/chemo sensitizing method effectively used in oncological treatments. These devices, which have been used effectively in many centers around the world in the treatment of cancer, are currently unavailable in our country. In this study, hyperthermia treatments that could be applied, the number of hyperthermia devices required and the potential effects in our country have been investigated in line with the applications of hyperthermia worldwide.Methods Based on the data obtained from certain reference centers the number and ratios of hyperthermia applications were determined and the data obtained was modeled according to the number of cancer cases in our country.Results According to the data obtained, an average of 375 patients are treated annually per hyperthermia device in relevant centers. When a similar projection is applied for our country, hyperthermia treatment can be applied to an average of 400 patients annually with 0,18 hyperthermia devices per one million population. According to this, considering the population and the annual cancer diagnosis rates, it is predicted that 13 deep regional hyperthermia devices are required across the country.Conclusion The presence of deep regional hyperthermia devices in comprehensive oncology centers that play an effective role in oncological treatment with modern radiotherapy devices and have enough radiation oncologists will significantly benefit the capacity to provide oncological treatment options holistically.

show abstract

“…Moreover, the role of hyperthermia in the treatment of cancer has been summarized in a study carried out by Sauer, R et al and published by the German Cancer Society in Sthrahlenther Oncol in 2012. This study is regarded as an explanatory text in which hyperthermia is recommended, especially in primary tumors and local recurrences (23). Hyperthermia is more than likely the most powerful radio-and chemo-sensitizer to date.…”

Section: Discussionmentioning

confidence: 99%

The Evaluation of Oncological Hyperthermia Centers and Turkey Modeling Oncological Hyperthermia Centers and Turkey Modeling

Göksel

Demircioğlu

2020

ircmj

View full text Add to dashboard Cite

Introduction and Objectives: The latest technology and current treatments are used in the treatment of cancer in Turkey; however, oncological hyperthermia devices are currently not available. This study aimed to demonstrate the necessity of oncological hyperthermia devices in Turkey where cancer treatment is performed effectively. In this direction, some important oncological hyperthermia centers have been examined to what kind of planning can be developed in this country. Materials and Methods: The data were collected regarding the number of patients who had undergone hyperthermia during the treatment of cancer and the distribution of oncological diagnoses, devices per population, and rate of hyperthermia use. Subsequently, a model was prepared for Turkey, and an evaluation was performed on the number of cancer patients that can be applied to this treatment and the need for the number of oncological hyperthermia devices. Results: According to the data obtained, an average of 375 patients are treated annually per hyperthermia device in relevant centers. When a similar projection is applied for Turkey, hyperthermia treatment can be applied to an average of 400 patients annually with 0.18 hyperthermia devices per one million population. According to this result, considering the population and the annual cancer diagnosis rates, it is predicted that 13 deep regional hyperthermia devices are required across the country. Conclusion: The presence of deep regional hyperthermia devices in comprehensive oncology centers plays an effective role in oncological treatment with modern radiotherapy devices. This condition along with the sufficient number of radiation oncologists will significantly benefit the capacity to provide oncological treatment options holistically.

show abstract

Concerning the final report “Hyperthermia: a systematic review” of the Ludwig Boltzmann Institute for Health Technology Assessment, Vienna, March 2010

Cited by 13 publications

References 18 publications

Modulated electro-hyperthermia in stage III and IV pancreatic cancer: Results of an observational study on 158 patients

Modulated electro-hyperthermia in stage III and IV pancreatic cancer: Results of an observational study on 158 patients

Evaluation of Oncological Hyperthermia Centers and Turkey Modeling Oncological Hyperthermia Centers and Turkey Modeling

The Evaluation of Oncological Hyperthermia Centers and Turkey Modeling Oncological Hyperthermia Centers and Turkey Modeling

Contact Info

Product

Resources

About